Can Boc-D-Phenylalaninol Deliver the Required (R)-Configuration for Hydroxyethylamine Isosteres?

N-Boc-D-phenylalaninol is used in medicinal chemistry routes as a chiral-pool starting material for the (2R,3S)-3-amino-2-hydroxy-4-phenylbutyl hydroxyethylamine transition-state isostere. The protected amine remains inert during activation of the primary hydroxyl and is removed only after the second asymmetric center has been introduced. This sequence appears in published programmes targeting aspartic protease families, including HIV-1 protease, renin, and β-secretase scaffolds. In these routes the benzyl group of the phenylalaninol component occupies the P1 pocket, while the hydroxyl and derived amine provide the transition-state-mimicking hydrogen-bond network.

In a representative activation sequence, the material is dissolved in anhydrous dichloromethane with water content not greater than 0.05% by Karl Fischer titration. The solution is cooled to 0–5 °C in a jacketed reactor with temperature control of ±2 °C. Triethylamine is charged at 1.2–1.5 equivalents, and methanesulfonyl chloride is metered in at 1.1–1.3 equivalents over 30–60 minutes. The methanesulfonate intermediate is held at 0–5 °C until HPLC-UV at 210 nm shows not more than 0.5 area% residual starting alcohol. Displacement with a primary amine is conducted at 40–50 °C for 12–24 hours with the amine charged at 2.0–3.0 equivalents. At pilot scale, the exotherm from sulfonyl chloride addition is controlled by dosing rate rather than reactor coolant temperature alone; the vessel is fitted with a slim-line thermocouple and a nitrogen-purged condenser. The activated intermediate is not isolated as a dry solid because residual sulfonyl chloride and moisture can promote premature hydrolysis and aziridine-forming side reactions.

After substitution, the tert-butoxycarbonyl group is removed with 4 M hydrogen chloride in 1,4-dioxane at 5–10 mL per gram of substrate. The deprotection is maintained at 20–25 °C for 1–3 hours and produces the hydrochloride salt of the secondary amino alcohol. The terminal intermediate is then carried into acylation or sulfonamide coupling without isolation of the free base. Residual solvents are controlled by USP <467>; water content is determined by USP <921>; and related substances are quantified by liquid chromatography per Ph. Eur. 2.2.29.

Oxazolidinone Auxiliary Formation from N-Boc Amino Alcohols

The protected amino alcohol is converted to (4R)-4-benzyloxazolidin-2-one, a chiral auxiliary used in asymmetric alkylation. In one route, the Boc group is first removed with hydrochloric acid in 1,4-dioxane at 20–25 °C. The resulting amino alcohol hydrochloride is suspended in tetrahydrofuran and neutralised with aqueous sodium hydroxide. Triphosgene is added at 0.35–0.40 equivalents relative to the free amino alcohol at −10 to 0 °C, followed by warming to 20–25 °C. The cyclisation step is exothermic; the triphosgene solution is transferred through a PTFE diaphragm pump into the reactor at a rate that keeps the internal temperature below 5 °C. A caustic scrubber is placed downstream of the inert gas vent because the reaction releases hydrogen chloride. Excess triphosgene is quenched with aqueous sodium bicarbonate before discharge. An alternative carbonyldiimidazole route uses 1.0–1.1 equivalents in dichloromethane at 20–25 °C and avoids phosgene-derived by-products but requires a longer stir time, typically 12–18 hours. The isolated oxazolidinone is then acylated with propionyl chloride after lithiation with n-butyllithium at −78 °C to generate an Evans-type acyl oxazolidinone. Residual solvents are limited by USP <467>; carbonylating reagent decomposition products are monitored by ion chromatography; and assay is measured by HPLC per Ph. Eur. 2.2.29. The terminal acyl oxazolidinone is used for the preparation of α-substituted carboxylic acid derivatives after deprotonation and alkylation.

When the primary alcohol is oxidized to N-Boc-D-phenylalaninal, the reaction is run under conditions selected to preserve α-carbon stereochemistry. Swern oxidation uses oxalyl chloride at 1.5 equivalents and dimethyl sulfoxide at 2.5 equivalents in dichloromethane at −78 °C. The activated dimethyl sulfoxide complex is formed for 30–45 minutes before the protected amino alcohol is added as a dichloromethane solution. Triethylamine is then introduced at 5.0 equivalents, and the reaction is warmed to 0 °C only after complete conversion. If the internal temperature rises above −50 °C during the sulfonium alkoxide stage, epimerisation of the resulting amino aldehyde becomes detectable by chiral HPLC. An alternative oxidation with Dess-Martin periodinane at 1.0–1.2 equivalents in dichloromethane at 20–25 °C avoids the deep-cool requirement but gives an iodinane-containing waste stream that must be reduced with sodium thiosulfate before aqueous work-up. At 5–10 L scale, the Swern route is run with a low-temperature circulation chiller and an in-pot thermocouple; the dimethyl sulfoxide also serves as the internal sacrificial oxidant. The resulting N-Boc-D-phenylalaninal is used directly in Horner-Wadsworth-Emmons olefination or reductive amination without isolation. The material is held at −20 °C under nitrogen and consumed within 8 hours to limit aldehyde dimerisation. Residual oxalyl chloride by-products are controlled by headspace gas chromatography per USP <467>; aldehyde assay is performed by HPLC after derivatisation with 2,4-dinitrophenylhydrazine in acetonitrile. The terminal product is an electrophilic amino aldehyde intermediate that enters olefination or imine chemistry.

Solution-Phase Peptide Alcohol Assembly: Coupling Reagent Stoichiometry and O-Acylation Boundaries

In solution-phase peptide chemistry, N-Boc-D-phenylalaninol is employed as a C-terminal amino alcohol building block for the preparation of peptide alcohol intermediates. The unprotected primary hydroxyl is nucleophilic under carbodiimide-mediated coupling conditions; therefore the carbodiimide is never used in large excess. A typical procedure activates the N-protected amino acid with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride at 1.0–1.2 equivalents and 1-hydroxybenzotriazole monohydrate at 1.0–1.2 equivalents in anhydrous N,N-dimethylformamide at 0–5 °C. N-Methylmorpholine is added at 1.0–1.1 equivalents to maintain the carboxylate concentration and to avoid hydrochloride precipitation. After 15 minutes of activation, N-Boc-D-phenylalaninol is added at 0.9–1.0 equivalents relative to the acid. The reaction is warmed to 20–25 °C and monitored by HPLC at 210 nm until residual acid is not more than 1.0 area%. The work-up involves dilution with ethyl acetate, sequential washes with 5% sodium bicarbonate solution and water, and drying over sodium sulfate. O-acylated side product, formed by acylation of the primary alcohol, is controlled by the stoichiometric limits and by slow addition of the amino alcohol at low temperature. The terminal protected peptide alcohol is isolated by crystallisation or silica chromatography and then deprotected for subsequent chain elongation or macrocyclisation. Residual N,N-dimethylformamide is controlled by USP <467>; chiral purity is measured by normal-phase HPLC on a polysaccharide-based chiral stationary phase per Ph. Eur. 2.2.29.

Direct O-acylation of BOC-D-Phenylalaninol with fatty acid chlorides provides protected amphiphilic amino alcohol intermediates for permeability screening and lipidated peptide conjugates. The N-Boc group remains intact under the mildly basic acylation conditions. The solid is dissolved in dichloromethane pre-dried to not more than 0.05% water by Karl Fischer titration, pyridine is charged at 1.2 equivalents, and the solution is cooled to 0–5 °C in a jacketed vessel. Palmitoyl chloride or a short-chain C6–C10 acyl chloride is metered in at 1.0–1.1 equivalents over 30 minutes. The reaction is aged at 0–5 °C until HPLC-UV at 210 nm shows not more than 0.5 area% residual starting alcohol. Aqueous sodium bicarbonate quench eliminates residual acid and pyridinium salt; the organic phase is washed with water and concentrated under reduced pressure at 35–40 °C. The resulting O-acyl intermediate is then treated with 4 M hydrogen chloride in 1,4-dioxane at 20–25 °C for 1–2 hours to remove the tert-butoxycarbonyl group and yield the amphiphilic amino alcohol hydrochloride. Competing hydrolysis of the acyl chloride is the principal process deviation; it is minimised by controlling the water content of the solvent and by keeping the system under a nitrogen blanket. Residual solvents are controlled by USP <467>, water content by USP <921>, and assay by liquid chromatography per Ph. Eur. 2.2.29. Terminal products are used directly in medicinal chemistry permeability assays or as lipophilic handles for further conjugate assembly.

Chiral Oxazoline Ligand Precursor Chemistry

After removal of the tert-butoxycarbonyl group, D-phenylalaninol is condensed with nitriles to yield 4-benzyl-2-substituted oxazolines, which are precursors to bis(oxazoline) ligands used in asymmetric catalysis. In a typical procedure, the hydrochloride salt is neutralised with sodium carbonate and partitioned into dichloromethane. The free amino alcohol is then combined with the nitrile at 1.0–1.5 equivalents and anhydrous zinc chloride at 1.0 equivalent in chlorobenzene. The mixture is heated at 130–140 °C for 12–24 hours with a Dean-Stark trap or molecular sieves to remove water generated during condensation. The reaction is monitored by HPLC; complete conversion is defined as not more than 1.0 area% residual amino alcohol. After cooling, the mixture is diluted with dichloromethane and washed with 5% sodium bicarbonate solution and ethylenediaminetetraacetic acid to reduce residual zinc. The organic phase is dried and concentrated, and the oxazoline is isolated by silica chromatography or vacuum distillation. Residual zinc is controlled by ICH Q3D; residual chlorobenzene is controlled by USP <467>; and chiral purity is confirmed by normal-phase HPLC on a chiral stationary phase per Ph. Eur. 2.2.29. The terminal oxazoline is subsequently deprotonated with n-butyllithium and treated with malonyl dichloride or malonate esters to form bis(oxazoline) ligands. Published data for the direct application of N-Boc-D-phenylalaninol in this specific Lewis acid-catalysed condensation is limited; the procedure is adapted from general amino alcohol oxazoline cyclisation methodology and should be verified against a qualified internal reference.

In registered intermediate campaigns, BOC-D-Phenylalaninol is qualified as a starting material under ICH Q11. The supplier certificate of analysis is compared against an internal specification before the material is charged into regulated steps. Identity is verified by infrared absorption spectrophotometry per Ph. Eur. 2.2.24, assay by liquid chromatography per Ph. Eur. 2.2.29, water content by Karl Fischer titration per USP <921>, residual solvents by headspace gas chromatography per USP <467>, and elemental impurities by ICH Q3D. The material is stored in sealed high-density polyethylene containers under nitrogen at 15–25 °C unless supplier stability data indicate deeper refrigeration. Batch-to-batch variance in residual solvent profile is monitored because dichloromethane and tetrahydrofuran can affect downstream crystallisation and O-acylation selectivity. The release process does not involve chemical transformation; its purpose is to ensure that the protected amino alcohol enters registered intermediate steps with defined purity, water content, and enantiomeric identity. The terminal output is a released starting material suitable for use in current good manufacturing practice synthesis of pharmaceutical intermediates.